275,922 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 275,922 shares of the medical equipment provider’s stock, valued at approximately $19,891,000. KLP Kapitalforvaltning AS owned about 0.12% of Hologic as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. General Partner Inc. bought a new stake in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.8 %

Shares of NASDAQ:HOLX opened at $61.47 on Monday. The business’s 50-day moving average is $66.06 and its 200 day moving average is $73.94. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The firm has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of several research reports. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and cut their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Citigroup reduced their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.